Onyx Pharmaceuticals

CBT Pharmaceuticals creates scientific advisory board

Monday, August 28, 2017

CBT Pharmaceuticals, a biopharmaceutical company focused on developing innovative oncology therapeutics harnessing the immune system and targeting specific molecular pathways to tame cancer,  announced the appointments of Robert A. Figlin, M.D., FACP and Frank McCormick, Ph.D., FRS, DSc. to its newly established Scientific Advisory Board (SAB).

[Read More]

Eric Morrie joins ClinCapture as director, Product Operations

Monday, April 11, 2016

Eric Morrie joins ClinCapture as director of Product Operations, bringing with him 20 years of experience in the clinical trial industry, including at some of the world’s leading pharmaceutical and medical device companies. The new addition to the executive management team brings ClinCapture’s experience and skill set to a new level.

[Read More]

EMD Serono appoints U.S. CMO

Wednesday, September 30, 2015

EMD Serono, the U.S. biopharmaceutical business of Germany-based Merck, has appointed Joseph Leveque, M.D., as U.S. chief medical officer. Leveque will be responsible for working with the regulatory, medical and development teams to enhance EMD Serono’s clinical presence in the U.S. and to drive the execution of crucial medical initiatives.

[Read More]

Bayer’s Stivarga receives FDA approval for GIST

Tuesday, February 26, 2013

The FDA has approved Bayer‘s Stivarga (regorafenib) tablets to treat patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.

[Read More]